Press Release – January 13, 2024
Announcing changes in the Editorial Board and Publishing Schedule
Verduci Editore is delighted to announce the appointment of Prof. Giuseppe Cirino as the new Editor-in-Chief of the European Review for Medical and Pharmacological Sciences as of January 2025. Supporting him in this prestigious role will be the newly appointed Associate Editors: Prof. Andreas Papapetropoulos, Prof. Fabrizio Gardoni, and Prof. Stefano Fiorucci.
Prof. Cirino brings a wealth of experience and a distinguished record of academic and editorial accomplishments, ensuring visionary leadership for the journal. Similarly, the Associate Editors, Profs. Papapetropoulos, Gardoni, and Fiorucci, are renowned experts in their respective fields, with extensive backgrounds in research, publication, and editorial management. Their proven abilities to navigate complex editorial processes and commitment to scientific rigor will be instrumental in advancing the journal’s mission of promoting high-quality research in medical and pharmacological sciences.
At the same time, Verduci Editore wishes to express its profound gratitude to Prof. Camillo Ricordi and Prof. David Della Morte Canosci for their exceptional service as Editor-in-Chief and Co-Editor-in-Chief, respectively, over the past three years. We are pleased to share that Prof. Ricordi and Prof. Della Morte Canosci will continue to serve the European Review for Medical and Pharmacological Sciences as senior members of the editorial board. Their continued involvement will undoubtedly be invaluable as the journal moves forward, building on the strong foundation they have established.
In addition, Verduci Editore announces a significant update to the journal’s publication schedule. Beginning in January 2025, the European Review for Medical and Pharmacological Sciences will transition from a fortnightly to a monthly publication schedule. This change reflects our commitment to ensuring the highest editorial standards and further enhancing the quality of published content. The new schedule will allow for more meticulous editorial processes, allowing the Editorial Board to dedicate greater attention to each issue and consistently implement the overall editorial procedures.
We are confident that the newly established editorial board and recent changes will bring fresh perspectives and expertise, positioning the journal to address emerging challenges and opportunities in pharmacological and medical research.
We extend our heartfelt congratulations to the new Editor-in-Chief and Associate Editors as they enter their roles. Their dedication will undoubtedly shape the future of this journal, and we are confident that their efforts will lead to continued success and innovation.
Editor in Chief
Prof. Giuseppe Cirino received his degree in Pharmacy from the University of Naples Federico II in 1980 and his PhD in Pharmacology in 1986. He has been a full Professor of Pharmacology since 2001. He is a member of the Italian Society of Pharmacology and a Fellow of both the British Pharmacological Society (FBPhS) and the Royal Society of Biology (FRBS).
He previously served as Head of the Department of Experimental Pharmacology and Dean of the Faculty of Pharmacy from 2006 to 2012. Additionally, he was Vice Rector for Teaching at the University of Naples Federico II until 2021. Since 2021, he has served as Vice Rector for Students’ Rights.
He has published over 300 peer-reviewed articles and several book chapters and is ranked among the top 100 Italian researchers in Pharmacology both globally and within Italy (Top Italian Scientists; http://www.topitalianscientists.org/Top_italian_scientists_VIA-Academy.aspx). He has also served as Senior Editor for the British Journal of Pharmacology and as Editor for Vascular Pharmacology and the Journal of Toxicological and Pharmacological Methods.
His primary research interests include cardiovascular and lung inflammation, as well as erectile dysfunction, with a particular focus on the gasotransmitters NO and H2S.
Associate Editors
Prof. Andreas Papapetropoulos earned his Bachelor’s in Pharmacy (University of Patras, Greece) and his PhD in Pharmacology (Medical College of Georgia, USA). He is currently Professor of Pharmacology at the Department of Pharmacy of the National and Kapodistrian University of Athens and Affiliated Investigator at the Biomedical Research Foundation of the Academy of Athens. He has been Adjunct/Visiting Professor at European (Maastricht University) and North American Universities (McGill University, Louisiana State University, University of Texas Medical Branch, University of Medicine and Dentistry New Jersey). He has served as a member of the editorial boards of journals published by British and American Pharmacological Societies and the American Heart Association. He has been elected Fellow of the American Heart Association and the British Society of Pharmacology, and President of the Federation of European Pharmacological Societies (EPHAR). He has published over 200 publications in peer-reviewed journals that have received 28,000 citations (h-index 76). His research focuses on the molecular mechanisms of drug action and the preclinical evaluation of novel drug candidates.
Prof. Stefano Fiorucci is a certified clinician and holds the Chair of Digestive and Liver Diseases at the University of Perugia. He is Associate Professor of Gastroenterology and Director of the Postgraduate Fellowship Program in Digestive Diseases at the University of Perugia, as well as Director of the PhD program in Clinical and Translational Medicine at the University of Perugia. Prof. Fiorucci has published over 450 original manuscripts in scientific journals. According to Google Scholar, his h-index is 90 and he has been ranked among the top 2% of scientists in the Stanford University/Elsevier database for 5 consecutive years (2020-24). Prof. Fiorucci ranks in the top 0.3% in the subfield of Gastroenterology and Hepatology. He is currently Editor, co-editor and is serving as an editorial board member of several scientific journals. Prof. Stefano Fiorucci is listed as an inventor in more than 20 granted patents and has received grants from national and international research organizations. He is the co-founder of three pharmaceutical companies.
Prof. Fabrizio Gardoni received his degree in Pharmaceutical Chemistry and Technology from the University of Milano in 1996 and a PhD in Toxicology in 2001. Since 2017, he has worked as a Full Professor of Pharmacology at the Department of Pharmacological and Biomolecular Sciences “Rodolfo Paoletti,” University of Milano. He has established a research line focusing on the understanding of the molecular mechanisms regulating the efficacy of the glutamatergic synapse and the key role of these events in neurodevelopmental and neurodegenerative diseases. Results obtained during his research activity are documented in more than 150 articles in peer-reviewed journals.
Prof. Gardoni is President of the Animal Welfare Committee at the University of Milano, a member of the Executive Council of the Italian Society of Pharmacology and a member of the Italian Society of Neuroscience. He has also served as Associate Editor for the Neurobiology of Disease journal.
Press release – November 4, 2024
Updates on the Journal’s Indexing Status
This press release is being issued to notify authors about updates to the journal’s indexing status. The journal’s current indexing is outlined on the homepage and has been updated accordingly as of November 2024. Additional details are available upon request; please contact us via email at submission.europeanreview@verduci.it.
We kindly ask authors to verify that the journal aligns with their indexing requirements at the time of submission or prior to publication.
Press release – July 22, 2024
Upholding scientific integrity: The journal’s latest actions
Science is continually evolving, and with its advancements, challenges are growing as well. As a matter of fact, the scientific community is experiencing significant challenges related to data integrity and ethical conduct in research. Data fabrication, figure manipulations, and related ethical concerns have emerged as significant issues encompassing a wide range of published literature and undermining the credibility of the research findings.
Both Editors and Publishers are responsible for maintaining the quality and reliability of published research by implementing the peer-review process, detecting malpractice, and avoiding the dissemination of fraudulent materials. This is a very challenging endeavor that confronts us with growing difficulties, which surely any Editor or Publisher is currently experiencing.
To address the need to enhance scientific integrity, the journal has made several adjustments in recent years to face the increasing dissemination of fraudulent science, which include, but is not limited to:
- Structural changes to the peer-review process, reinforcing its role as the backbone of scientific publication. Additional rigorous checks have been integrated into the review process, and the online submission platform has been introduced to assist reviewers with a checklist summarizing evaluation parameters for more accurate assessments.
- Enhancement of the guidelines for conducting fair and concise peer-review by detailing how to manage various scenarios, including suspected undeclared conflicts of interest or ethical misconduct.
- In addition to stringent policies requiring detailed methodological descriptions and the submission of uncropped original figures, the journal has subscribed to advanced software for detecting image manipulation and plagiarism to assist reviewers and editors in the final assessment of submissions and to address post-publication allegations.
European Review for Medical and Pharmacological Sciences is committed to promoting ethical research and publishing higher standards of research, which also implies correcting or retracting any previously published material that does not adhere to international standards and/or presents data manipulation issues.
With the aid of new tools, the journal is checking and screening previously published articles in an effort to promote data integrity and good science. As a result, over the past years, the journal has launched a robust campaign to retract all articles that do not meet these standards.
Investigations into alleged misconduct are very complex and time-consuming. The solution is not always straightforward or easy to take, and it requires great collaboration between editors, reviewers, authors, and institutions.
We also take the opportunity to update readers regarding the published Expression of Concern for the Special Issue “Omics sciences in the personalization of diagnosis and therapy”. The first part of the investigation has been concluded and has resulted in the retraction of 5 articles and the publication of 3 errata. The investigation of the remaining articles is still ongoing, and we hope to publish updates as soon as possible.
The Publisher and the Editorial board apologize again for the inconvenience and renew their gratitude to all the independent researchers and readers who helped identify such issues.
Prof. Camillo Ricordi, MD, FNAI, Editor in Chief
Verduci Editore
Press Release – January 26, 2024
Announcing new updated editorial guidelines for Special Issues and Supplements
European Review for Medical and Pharmacological Sciences has updated its editorial guidelines concerning the publication of Special Issues and Supplements.
Following the new DOAJ criteria and COPE guidelines, released in November and May 2023, respectively, the new guidelines update the existent criteria concerning the authorship and Guest Editors’ role within the articles included in Special Issues and Supplements, with a particular focus on the peer-review process, the contribution of authors and Guest Editors in each article and the conflicts of interest.
The new guidelines are already available in the Instructions for Authors.
Press Release – June 28, 2022
Eur Rev Med Pharmacol Sci announces the new 2021 Impact Factor release
European Review for Medical and Pharmacological Sciences is pleased to share the great success achieved this year with the new Impact Factor of 3.784. We would like to thank all our Authors who are the ones ultimately responsible for the significant growth of the Journal and invite them to submit new research.
Press Release – August 5, 2021
Eur Rev Med Pharmacol Sci indexed in DOAJ
We are glad to announce that Eur Rev Med Pharmacol Sci has just been indexed in the Directory of Open Access Journals (DOAJ) thanks to the remarkable improvements that have been made in the journal’s quality over the last few years. DOAJ is a well-known community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals (https://doaj.org/).
Press Release – July 15, 2021
Announcing changes in the Editorial Board
Verduci Editore is pleased to announce the appointment of Prof. Camillo Ricordi as Editor-in-Chief and Prof. David Della Morte Canosci as Co-Editor-in-Chief of European Review for Medical and Pharmacological Sciences.
Verduci Editore is deeply grateful to Prof. Antonio Gasbarrini and to Prof. Aldo V. Greco for their service as Editors in Chief and for their contribution to the growth of European Review for Medical and Pharmacological Sciences over the past decades. They supported the journal handling a successful and ongoing increase and contributing in different ways to the development of the journal.
Editor in Chief,
Camillo Ricordi, MD, FNAI
Prof. Camillo Ricordi, is the Stacy Joy Goodman Professor of Surgery and Director of the Diabetes Research Institute and the Cell Transplant Center at the University of Miami, Miami, Florida, USA.
Acknowledged as a leading scientist in diabetes cure-focused research and cell transplantation, Ricordi is known for inventing the method that made it possible to isolate large numbers of insulin-producing cells from the human pancreas and for performing the first series of successful clinical islet allotransplants that reversed diabetes. The procedure is now used worldwide, including the first successful NIH-funded, FDA Phase 3 multicenter trial completed by the NIH Clinical Islet Transplantation Consortium where Ricordi served as Chairperson of the Steering Committee for over a decade. His research interests include reversal of autoimmunity, transplant tolerance, modulation of immunity and inflammation and regenerative medicine, to prevent or treat chronic degenerative disease conditions, and to prolong healthy lifespan.
When the COVID-19 pandemic emerged, Prof. Camillo Ricordi led the international team that successfully completed the first FDA-approved double-blind, randomized, placebo-controlled clinical trial to treat severe cases of COVID-19 ARDS with Umbilical Cord derived Mesenchymal Stem Cell infusions. The unprecedented results allowed for significantly improved time to recovery and patient survival in subjects treated. Ricordi and his collaborators have recently launched the Fit4Pandemic program (www.fit4pandemic.com) to help the general population become resistant to the most severe forms of viral infections, as well as to prevent or halt the progression of autoimmune diseases and age-related chronic degenerative conditions, to prolong healthy lifespan.
Prof. Camillo Ricordi has received numerous honors and awards, including the Outstanding Scientific Achievement Award by the American Diabetes Association. He was Knighted by the President of the Republic of Italy in the highest Order of the Republic (the Order of Merit), and was inducted into the National Academy of Inventors, USA, for contributing outstanding inventions that have made a tangible impact on the quality of life, economic development, and welfare of society. He is also serving on the Supreme Council of Health (Consiglio Superiore di Sanità) of the Ministry of Health of Italy.
Camillo Ricordi is author of over 1,150 scientific publications that have been cited over 45,700 times (H-index 102).
Co-Editor-in-Chief,
David Della Morte Canosci, MD, PhD
Prof. David Della Morte Canosci serves as an Associate Professor of Neurology at the University of Miami, Miami, USA. Since 2013, he is also Associate Professor of Internal Medicine, Department of Systems Medicine, University of Tor Vergata, Rome, Italy, and a collaborator of the San Raffaele Open Rome, Italy. Prof. Della-Morte is involved in both basic and clinical science in the field of aging, metabolic, genetic, cardiovascular, and cerebrovascular disease. His current research focus is to clarify the pathological pathways linking metabolic diseases with cognitive impairment typical of elderly patients and with genetic disorders. Prof. Della Morte Canosci authored more than 200 scientific articles in international peer-reviewed journals. He was recipient of several grants from American Heart Association and NIH and was awarded from many Scientific Societies. He is on the board membership of several journals, and a member of The European Foundation for the Study of Diabetes and other important professional organizations.